Medical Crossfire®: Translating Risk Into Action—Redefining Adjuvant Strategies for Early HR+/HER2– Breast Cancer

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Ann H. Partridge, MD, MPH; Saranya Chumsri, MD; and William J. Gradishar, MD, FASCO, FACP, discuss the roles of adjuvant chemotherapy and CDK4/6 inhibitors and neoadjuvant checkpoint inhibitors for patients with early-stage, hormone receptor–positive breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate clinical evidence supporting the use of current and emerging therapies in the adjuvant treatment of HR+/HER2– early breast cancer
• Design individualized treatment strategies that incorporate genomic profiling and clinicopathologic risk factors to optimize outcomes in patients with early-stage HR+/HER2– breast cancer

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from Exact Sciences Corporation; Hologic, Inc; and Lilly.

Chair:

Ann H. Partridge, MD, MPH

Professor of Medicine
Harvard Medical School
Eric P. Winer, MD, Chair in Breast Cancer Research
Vice Chair, Department of Medical Oncology
Co-founder and Director, Program for Young Adults with Breast Cancer
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Ann H. Partridge, MD, MPH, has no relevant financial relationships with ineligible companies.

Faculty:

Saranya Chumsri, MD

Oncologist
Division of Hematology and Medical Oncology
Mayo Clinic
Jacksonville, FL

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Biotheranostics, Daiichi Sankyo, Eisai, Genentech, Menarini Stemline, Novartis, Pfizer, Puma Biotechnology, Seagen; Grant/Research Funding: BriaCell Therapeutics, Merck & Co, Novartis, Pfizer, Salix Pharmaceuticals

William J. Gradishar, MD, FASCO, FACP

Betsy Bramsen Professor of Breast Oncology and Professor of Medicine
Chief, Division of Hematology/Oncology
Feinberg School of Medicine at Northwestern University
Chicago, IL

Disclosures: Co-Investigator: Gilead, Menarini Group, Pfizer; Data Monitoring Committee: Lilly, Menarini Group

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on the optimal duration of endocrine therapy for hormone receptor–positive early breast cancer, go to https://www.gotoper.com/courses/medical-crossfire-translating-risk-into-actionredefining-adjuvant-strategies-for-early-hrher2-breast-cancer.

Release Date

April 14, 2026

Expiration Date

April 14, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.